Pluriomics receives a €3.2M grant under the Horizon 2020 SME instrument programme to advance cardiovascular drug discovery

Leiden, The Netherlands, June 16, 2016 – Pluriomics, an emerging Dutch/Belgian biotechnology company whose mission is to deliver innovative human cardiomyocyte assays for use in drug discovery & development, today announced it was awarded a prestigious EU SME instrument grant. This grant gives Pluriomics the opportunity to advance cardiovascular drug discovery, in order to reduce […]

READ MORE read more

Pluriomics CEO is a co-author of a new book entitled “Stem Cell-Derived Models in Toxicology”

Leiden, The Netherlands, December 2, 2016 –  Stefan Braam (Pluriomics CEO) and Gary Gintant (Abbvie) co-published a chapter in the “Stem Cell-Derived Models in Toxicology” book underlying the added value of Stem Cell-Derived Models for Safety and Toxicity Assessments. The promise of human, stem cell-derived models for safety and toxicity assessments remains great. Using such preparations, […]

READ MORE read more

News archive

Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update Meeting 2016

Location: Rockville, MD, USA Date: December 6 – 7, 2016 Pluriomics will attend the Comprehensive In Vitro Proarrhythmia Assay (CiPA) Update Meeting in Rockville, MD, USA.   The Comprehensive In Vitro Proarrhythmia Assay (CiPA) seeks to markedly transform the assessment of drugs for their proarrhythmic potential, replacing the current focus on ECG QT assessment. This multi-national effort is moving […]

READ MORE read more

WPC: World Preclinical Congress, Europe 2016

Location: Lisbon, Portugal Date: November 15 – 16, 2016 Pluriomics will attend the WPC Europe in Lisbon, Portugal The World Preclinical Congress Europe is a key networking event bringing together a global audience involved in preclinical research. Don’t miss the opportunity to meet Dr. Marijn Vlaming, VP Technology at Pluriomics, who will attend the “Optimizing Leads […]

READ MORE read more

Events archive

About us

Pluriomics develops and commercializes fully functional, human iPSC-derived cardiomyocytes and provides high quality services for efficient and reliable safety pharmacology testing and cardiovascular drug efficacy screening.

Pluriomics, a leading expert in human cardiovascular stem cell technology, manufactures fully functional human iPSC derived cardiomyocytes (Pluricyte® Cardiomyocytes) using well-defined, serum-free medium that enhances the maturation and function of the cells. Pluriomics combines Pluricyte® Cardiomyocytes with innovative technologies to develop in-house cell-based assays with the objective to improve drug safety and efficacy screening.

Read more

Pluricyte® Cardiomyocyte Kit

Pluricyte® Cardiomyocyte Kit is developed and manufactured for use in drug discovery and development. The kit includes both Pluricyte® Cardiomyocytes and Pluricyte® Cardiomyocyte Medium (serum-free).

iView product information

Our solutions